First Reported Successful Femoral Valve-in-Valve Transcatheter Aortic Valve Replacement Using the Edwards Sapien 3 Valve

J Invasive Cardiol. 2015 Oct;27(10):E220-3. Fournier S, Monney P, Roguelov C, Zuffi A, Iglesias JF, Qanadli SD, Courbon C, Eeckhout E, Muller O. Management of degenerated aortic valve bioprosthesis classically requires redo surgery, but transcatheter aortic valve-in-valve implantation is becoming a valid alternative in selected cases. In the case of a degenerated Mitroflow bioprosthesis, TAVR is associated with an additional challenge due to a specific risk of coronary occlusion. We aimed to assess the safety and feasibility of transfemoral valve-in-valve implantation of the new Edwards Sapien 3 (Edwards Lifesciences) in a degenerated Mitroflow bioprosthesis (Sorin Group, Inc).

References

  • Fournier S, Monney P, Roguelov C, Zuffi A, Iglesias JF, Qanadli SD, Courbon C, Eeckhout E, Muller O1. First Reported Successful Femoral Valve-in-Valve Transcatheter Aortic Valve Replacement Using the Edwards Sapien 3 Valve. J Invasive Cardiol. 2015 Oct;27(10):E220-3. PMID: 26429854.